Sun Pharma Informs about SEBI's Special Window for Physical Share Transfers
Sun Pharma announces SEBI's special window for physical share transfers, open from Feb 5, 2026, to Feb 4, 2027. This facilitates transfers of shares sold/purchased before April 1, 2019. Transferred shares will be credited to demat accounts and locked in for one year.
This is a regulatory compliance announcement concerning a SEBI-led initiative for investors, with no direct immediate financial or operational impact on Sun Pharma itself.
The announcement is a routine regulatory disclosure regarding a SEBI initiative and does not contain information that positively or negatively impacts the company's financial performance or operations.
Sun Pharmaceutical Industries Limited has announced the opening of a special window by SEBI for the transfer of physical shares. This window, effective from February 5, 2026, to February 4, 2027, allows for the transfer of physical shares sold or purchased before April 1, 2019. This initiative aims to facilitate ease of investing and secure the rights of investors.
During this period, any shares transferred must be credited to the transferee's demat account and will be under a lock-in for one year from the registration date. These shares cannot be transferred, lien-marked, or pledged during the lock-in period. Investors are encouraged to submit necessary documents, including original share certificates, transfer deeds executed before April 1, 2019, proof of purchase, KYC documents, and client master lists, to the Registrar and Transfer Agent, MUFG Intime India Private Limited, within the specified timeframe.
In compliance with SEBI regulations, the company published newspaper advertisements on February 6, 2026, in the Financial Express (English and Gujarati editions) and will also post information on social media platforms like X, LinkedIn, and Facebook regarding this special window.
What to do with a filing like this
Sun Pharmaceutical Industries Limited filed this with the NSE as a statutory disclosure, categorised under regulatory impact. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Sun Pharmaceutical Industries Limited. Read the original for the full detail.